220 results about "Cardiovascular event" patented technology

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and/or diabetes.

Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.

The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Methods and apparatus are provided for assessing the risk of an acute cardiovascular event that includes providing an endothelial or vascular function test to identify higher risk from lower risk individuals in a population of symptomatic individuals presenting with chest pain that have inconclusive results in ECG and cardiovascular marker tests, such as a tropinin test, and are administered for triage in hospital and additional tests such as ECG exercise and nuclear stress tests. The invention further provides methods and apparatus for assessing the vascular status and response of patients in clinical trials for cardiovascular therapies.

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

The invention discloses a prediction device for cardiovascular adverse events of percutaneous coronary intervention based on machine learning. The prediction device is characterized in that a cardiovascular event prediction model is saved in a memory, the cardiovascular event prediction model comprises a trained XGboost model, a LightGBM model, an SVM model, an NN model and corresponding weights of each model. The operating process of the prediction device comprises the steps that to-be-detected clinical characteristic data is received, missing value filling is conducted on the to-be-detectedclinical characteristic data; correlation detection is conducted on the clinical characteristic data on which missing value filling is conducted, and the clinical characteristic value with a crossed relationship is removed; computation is conducted on the clinical characteristic data on which correlation detection is conducted using the trained XGboost model, the LightGBM model, the SVM model andthe NN model to obtain four prediction probabilities, and weighted summation is conducted on the four prediction probabilities to obtain the prediction probability predicted by using the cardiovascular adverse event prediction model.

Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease or having a recurrent cardiovascular event wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.

The invention relates to a method of treatment or prevention of acute coronary syndrome or related conditions or reducing the risk of cardiovascular events comprising the administration of a therapeutically or prophylactically effective amount of meloxicam in combination with a therapeutically or prophylactically effective amount of an antiplatelet agent to a patient in need of such treatment. The invention also provides pharmaceutical compositions comprising meloxicam and an antiplatelet agent as a combined preparation suitable for use in these indications. Furthermore, the invention provides the use of meloxicam for manufacture of a pharmaceutical composition for treatment or prevention of acute coronary syndrome and related conditions when used in combination with an antiplatelet agent.

The present invention is a non-invasive apparatus, system, and method for performing irradiation light therapy upon blood circulating within the nostrils of a living mammalian subject. The merit and medical value of the invention resides in its ability to achieve a reversal of red blood cell aggregation in-vivo without invading the tissues or organs of the living subject—a clinical result which leads to lower blood viscosity and improved blood circulation. In this manner, the invention provides the living mammalian subject with an enhanced immunity from diseases, a reduced vulnerability to hypertension, and a reduced risk of a cardiovascular incident. Furthermore, by altering the wavelengths transmitted by the light generating unit(s) and controlling the light energy dosage, the method and system can also fine-tuned further as intervention for various diseases.

The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.

A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.